Lactate Dehydrogenase Enzyme Level in Women with Severe Preeclampsia: A Cross-sectional Study

Nadia Hameed [a≡], Yasmeen Bibi [b≡], Shehreen Memon [c≡], Sanam Channa [dφ], Muhammad Ali Memon [e#] and Muhammad Nadeem Chohan [f†*]

[a] *Sindh Government Pediatric Hospital Phuleli, Hyderabad, Pakistan.*
[b] *Hazrat Khadija Hospital latifabad, Pakistan.*
[c] *Bhittai Government Hospital Latifabad, Hyderabad, Pakistan.*
[d] *CMW School Tando Muhammad Khan, Pakistan.*
[e] *Department of Medicine, LUMHS, Hyderabad, Pakistan.*
[f] *Pediatric Department, LUMHS, Jamshoro, Pakistan.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Original Research Article

ABSTRACT

Aim: To determine the frequency of raised lactate dehydrogenase enzyme in women with severe preeclampsia.
Study Design: Cross-sectional study.
Place and Duration: Obstetrics and Gynecology department at Liaquat University Hospital Hyderabad from June 2018 to December 2018.
Methodology: There were 141 primiparous women with severe preeclampsia, included in this study. After taking history regarding hypertension and obstetrical examination, patients were subjected to a relevant investigation that is, 5ml of blood sent to an institutional laboratory for the measurement of lactate dehydrogenase enzyme, if it is >400 U/L then it was labeled as raised.
Results: The frequency of raised lactate dehydrogenase enzyme (400 U/L) was 13.48% (19/141) women with severe preeclampsia.

_____

≡*Medical Officer;*
φ*Clinical Instructor;*
#*FCPS;*
†*FCPS, Assistant Professor;*
*Corresponding author: E-mail: nadeem.chohan@lumhs.edu.pk, nadeemchohanpink76@yahoo.com;

Conclusion: About 14% of women having Pre-eclampsia had raised lactate dehydrogenase enzyme. Severe preeclampsia is associated with severe multisystemic involvement. Raised LDH levels are indicative of cellular damage and severe hypertension in pregnancy.

1. INTRODUCTION

Globally preeclampsia is responsible for fetal and maternal mortality and morbidity [1].

It causes vascular dysfunction and vasospasm. It usually occurs after 20 weeks of pregnancy but it can occur 4-6 weeks postpartum. It is defined as proteinuria, hypertension with or without edema [2]. Preeclampsia affects about 5-10% of all pregnancies [3] and the exact incidence of pre-eclampsia is unknown, but in the United States, it ranges from 2% to 6% in healthy women [4,5].

Hypertension during pregnancy is responsible for significant maternal and fetal morbidity and mortality [6]. Although eclampsia is a lethal condition preeclampsia caused more death comparatively. Pregnancy-induced hypertension (Eclampsia, Preeclampsia) manifests in the third trimester of pregnancy [7].

About 15% of pregnancies manifest as mild preeclampsia, 8% as moderate, and 2% as severe preeclampsia [8]. Altered endothelial cell function is the pathognomic factor in preeclampsia. The lactate dehydrogenase enzyme (LDH) rises in case of tissue damage. Normally LDH is present in many tissues like cardia, renal, hepatic, and pulmonary tissues. Endothelial cell dysfunction causes platelet aggregation and vasoconstriction, all of these leads to hypertension and atherosclerosis [9]. Levels of LDH in preeclampsia are directly related to fetal outcomes [10].

Preeclampsia causes a lot of changes in the cardiovascular system [11]. As a biomarker, LDH levels reflect the severity of preeclampsia [12].

According to a study hypertension and raised diastolic blood pressure are very common in preeclampsia women [13].

The objective of this study is to pick up the severity of disease at an earlier stage so that major complications including HELLP syndrome could be prevented by means of earlier and timely intervention and further management can be planned and implemented in order to reduce maternal illness, fetal illness, and death.

2. METHODOLOGY

This Cross-sectional study was conducted at Obstetrics and Gynecology Department, Liaquat University Hospital Hyderabad from June to December 2018 by non-probability consecutive sampling technique. Total 141 primiparous women aged 20-35 years with severe preeclampsia were included in the study. Women having a history of chronic hypertension, diabetes mellitus, urinary tract infection, fetal congenital anomaly, or epilepsy were excluded.

Preeclampsia is defined as the development of new hypertension after 20th-week gestation that is accompanied by new-onset proteinuria. Severe preeclampsia is defined as systolic blood pressure >160 mmHg and > 300 milligrams of protein collected in a 24-hour urine sample after the 20th week of gestation.

Primiparous women with severe preeclampsia visiting OPD of Liaquat university hospital with raised blood pressure were enrolled in the study. After taking history regarding hypertension and obstetrical examination, the patient was subjected to relevant investigation i.e. 5 ml of blood sent to the institutional laboratory for the measurement of lactate dehydrogenase enzyme, if it is >400 U/L was labeled as significant. Age, economic status, educational status, and LDH level were noted and entered into the proforma. After the collection of data, the analyses were conducted by using Statistical Package for Social Science (SPSS) software version 22. Mean and standard deviation were calculated for the quantitative variable is age and levels of Lactate Dehydrogenase (LDH). Frequency and percentages were computed for qualitative variables like raised LDH, educational status, and economic status. Effect modifier age, educational status, economic status, and gestational age were controlled by stratification. A Chi-square test was applied. P-value <0.05 was taken as significant.

3. RESULTS

There were 141 primiparous women aged 20-35 years with severe preeclampsia were included in this study. Most of the patients were 20 to 30 years of age. The average age of the patients was 25.91±3.33 years similarly the average Lactate dehydrogenase Level (LDL) was 386.96 ± 163.95 U/L as presented in Table 1.

Most of the socio-economic status was low (family income < 10K) rupees) that is 65.25% (92/141) and 25.53% (36/141) belonged to the middle class (family income: 10K to 30K). Regarding the educational status of the study patients, 63.12% were illiterate, 21.28% were primary educated and 15.6% metric.

The frequency of raised lactate dehydrogenase enzyme was 13.48% (19/141) women with severe preeclampsia. With respect to age groups, raised lactate dehydrogenase (LDH) was 43.8% (7/16) in 31 to 35 years of age patients, 17.9% (10/141) in 26 to 30 years of age patients, and 2.9% (2/69) in 20 to 25 years of age cases. The rate of LDH was significantly high in 31 to 35 years of patients (p=0.0005) as shown in Table 2. The rate of LDH was insignificant between gestational ages (Table 3) while LDH was high in lower socioeconomic status (16.3%) but statistically insignificant among the socioeconomic class as presented in Table 4. Table 5 showed that the rate of LDH was also insignificant among the education level of the patients.

Table 1. Descriptive statistics of patients

Statistics		Age (Years)	Lactate Dehydrogenase Level
Mean		25.91	386.96
95% Confidence Interval for Mean	Lower Bound	25.36	359.67
	Upper Bound	26.47	414.26
Median		26	350
Std. Deviation		3.33	163.95
Minimum		20	120
Maximum		35	850

Table 2. Frequency of raised lactate dehydrogenase enzyme in women with severe preeclampsia with respect to age groups

Age Groups (Years)	Raised lactate dehydrogenase		Total	P-Value
	Yes	No		
20 to 25	2 (2.9%)	67 (97.1%)	69	0.0005
26 to 30	10 (17.9%)	46 (82.1%)	56	
31 to 35	7 (43.8%)	9 (56.3%)	16	

Chi-Square= 20.12

Table 3. Frequency of raised lactate dehydrogenase enzyme in women with severe preeclampsia with respect to gestational age

Gestational Age (Weeks)	Raised lactate dehydrogenase		Total	P-Value
	Yes	No		
28 to 34	11 (13.8%)	69 (86.3%)	80	0.91
>34	8 (13.1%)	53 (86.9%)	61	

Chi-Square= 0.012

Table 4. Frequency of raised lactate dehydrogenase enzyme in women with severe preeclampsia with respect to socioeconomic status

Socioeconomic Status	Raised lactate dehydrogenase		Total	P-Value
	Yes	No		
Lower	15(16.3%)	77(83.7%)	92	0.40
Middle	3(8.3%)	33(91.7%)	36	
High	1(7.7%)	12(92.3%)	13	

Chi-Square= 1.82

Table 5. Frequency of raised lactate dehydrogenase enzyme in women with severe preeclampsia with respect to educational level

Educational level	Raised lactate dehydrogenase		Total	P-Value
	Yes	No		
Illiterate	10(11.2%)	79(88.8%)	89	0.032
Primary	7(23.3%)	23(76.7%)	30	
Metric	2(9.1%)	20(90.9%)	22	

Chi-Square= 0.197

4. DISCUSSION

In our study, older age was more often seen in women with severe pre-eclampsia group.

With respect to age groups, raised lactate dehydrogenase was 43.8% (7/16) in 31 to 35 years of age patients, 17.9% (10/141) in 26 to 30 years of age patients, and 2.9% (2/69) in 20 to 25 years of age cases. The rate of LDL was significantly high in 31 to 35 years of patients (p=0.0005).

Serum biomarkers like LDH are prognostics in detecting the severity of preeclampsia. Although other biomarkers like uric acid and ALT are also prognostics LDH level is more reliable among them. In the present study, the average age of the patients was 25.91±3.33 years and the average Lactate dehydrogenase Level (LDL) was 386.96 ± 163.95 U/L. The frequency of raised lactate dehydrogenase enzyme was 13.48% (19/141) women with severe preeclampsia. Similarly in a study, most of the women belonged to the age group of 20-25 years and the mean LDH was significantly higher in women with preeclampsia as compared to normal pregnant women [14].

Furthermore, in an Indian study, 30.8% of women had high LDH levels among them half had severe preeclampsia while the remaining 50% had mild preeclampsia. The rise in the LDH levels was observed with increasing severity of preeclampsia [15]. In another similar Pakistani study, the mean LDH was 337.89±173.15 in mild preeclampsia while it was 556.41±193.02 in severe preeclampsia. It signifies that LDH level increases with the severity of preeclampsia [16].

An international study concludes a positive correlation between increasing severity of preeclampsia and median LDH concentrations (p = 0.037) [17]. According to the results of a study mean LDH was normal (257.24 U/L) in normotensive pregnant women, it increased to 417.84 U/L in preeclampsia while it increased significantly (565.51 U/L) in eclampsia women [18].

Maternal and perinatal morbidity and mortality are linked to hypertension in pregnancy. A number of studies reflected on the magnitude of this problem globally. Elevated levels of LDH in severe preeclampsia are associated with fetal problems like low birth weight, low Apgar score, and neonatal mortality. Although we did not monitor the fetal and neonatal outcome in our study but is proven in other studies [19,20].

5. LIMITATIONS OF THE STUDY

It was a cross-sectional single-center study with a small sample size, so further cohort studies at various hospitals should be conducted to validate the results.

6. CONCLUSION

In our study about 14% of women having Pre-eclampsia had raised lactate dehydrogenase enzyme. Severe preeclampsia is associated with severe multisystemic involvement. Raised LDH levels are indicative of cellular damage and severe hypertension in pregnancy.

DISCLAIMER

The products used for this research are commonly and predominantly used products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by the personal efforts of the authors.

ETHICAL APPROVAL AND CONSENT

The study was performed after the permission of the ethical committee of the hospital, and verbal

informed consent for the study from the study participants.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Fox R, Kitt J, Leeson P, Aye CY, Lewandowski AJ. Preeclampsia: risk factors, diagnosis, management, and the cardiovascular impact on the offspring. Journal of Clinical Medicine. 2019;8(10): 1625.
2. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, challenges, and perspectives. Circulation Research. 2019; 124(7):1094-112.
3. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia prevalence, risk factors, and pregnancy outcomes in Sweden and China. JAMA Network Open. 2021;4(5):e218401.
4. Moore, Thomas R. Hypertensive complications of pregnancy. Avery's Diseases of the Newborn. Elsevier. 2018; 119-125.
5. Shahul S, Medvedofsky D, Wenger JB, Nizamuddin J, Brown SM, Bajracharya S, Salahuddin S, Thadhani R, Mueller A, Tung A, Lang RM. Circulating antiangiogenic factors and myocardial dysfunction in hypertensive disorders of pregnancy. Hypertension. 2016;67(6): 1273-80.
6. Duhig K, Vandermolen B, Shennan A. Recent advances in the diagnosis and management of pre-eclampsia. F1000 Research. 2018;7.
7. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018; 72(1):24-43.
8. Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PloS One. 2014;9(12): e113715.
9. Ford TJ, Ong P, Sechtem U, Beltrame J, Camici PG, Crea F, Kaski JC, Bairey Merz CN, Pepine CJ, Shimokawa H, Berry C. Assessment of vascular dysfunction in patients without obstructive coronary artery disease: why, how, and when. Cardiovascular Interventions. 2020; 13(16):1847-64.
10. Espinoza J, Vidaeff A, Pettker CM, Simhan H. Gestational Hypertension and Preeclampsia. Obstetrics and Gynecology. 2020;135(6):E237-60.
11. Ridder A, Giorgione V, Khalil A, Thilaganathan B. Preeclampsia: the relationship between uterine artery blood flow and trophoblast function. International Journal of Molecular Sciences. 2019; 20(13):3263.
12. Mehta M, Parashar M, Kumar R. Serum lactate dehydrogenase: A prognostic factor in pre-eclampsia. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2019;8(7):2792-9.
13. Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. SAGE Open Medicine. 2019; 7:2050312119843700.
14. Gupta A, Bhandari N, Kharb S, Chauhan M. Lactate dehydrogenase levels in preeclampsia and its correlation with maternal and perinatal outcome. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2019;8(4):1505-11.
15. Kharb S, Bhandari N, Singh A, Gupta A. Lactate dehydrogenase and maternal and perinatal outcome in preeclamptic women. Archives of Medicine and Health Sciences. 2019;7(2): 163.
16. Kasraeian M, Asadi N, Vafaei H, Zamanpour T, Shahraki HR, Bazrafshan K. Evaluation of serum biomarkers for detection of preeclampsia severity in pregnant women. Pakistan Journal of Medical Sciences. 2018;34(4):869.
17. Vazquez-Alaniz F, Salas-Pacheco JM, Sandoval-Carrillo AA, La-llave-Leon O, Hernandez EM. Lactate Dehydrogenase in Hypertensive Disorders in Pregnancy: Severity or Diag-nosis Marker. J Hypertens Manag. 2019;5:040.
18. Kulkarni VV, Shaikh B. To Study Levels of LDH in Normal Pregnancy, Pre-Eclampsia & Eclampsia. Journal of Evolution of

Medical and Dental Sciences. 2019; 8(35):2768-73.

19. Singh P, Gaikwad HS, Marwah S, Mittal P, Kaur C. Role of Serum Lactate Dehydrogenase in Pregnancy Induced Hypertension with its Adverse Feto-Maternal Outcome-A Case-control study. Journal of Clinical & Diagnostic Research. 2018;12(5).

20. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, Abdollahi M. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020; 396(10258):1204-22.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/82403